<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03264547</url>
  </required_header>
  <id_info>
    <org_study_id>JBCRG-M06</org_study_id>
    <nct_id>NCT03264547</nct_id>
  </id_info>
  <brief_title>A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab</brief_title>
  <official_title>A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar
      PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent
      HER2-positive breast cancer patients who have no medical history of chemotherapy except
      ado-trastuzumab emtansine
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>5.75 years</time_frame>
    <description>Progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RR</measure>
    <time_frame>5.75 years</time_frame>
    <description>Response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DR</measure>
    <time_frame>5.75 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>6.25 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRO</measure>
    <time_frame>5.75 years</time_frame>
    <description>Patient-reported outcomes(Numbness &amp; tingling)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>5.75 years</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomaker</measure>
    <time_frame>5.75 years</time_frame>
    <description>DNA mutation in the ctDNA and tumor tissue such as HER2,HER3, and PIK3CA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nMFS</measure>
    <time_frame>5.75 years</time_frame>
    <description>new Metastases free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTF of the subsequent treatment</measure>
    <time_frame>5.75 years</time_frame>
    <description>Treatment duration of the following treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab + pertuzumab + Taxane*
*Taxane is chosen from the following; Docetaxel or Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab+ Pertuzumab + Eribulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Every 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Every 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Every 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Every week</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <description>Administered for 2 weeks and is then stopped to be administered for 1 week</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Halaven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with breast cancer that is confirmed histologically or cytologically

          2. Patients who are confirmed to be HER2 positive for the primary or a metastatic lesion
             at a participating medical institution

          3. Patients with no medical history of treatment for advanced/recurrent cancer using a
             regimen of drugs including chemotherapeutics

          4. &gt;=6 months have passed since perioperative treatment with anticancer agents

          5. Presence of a measurable lesion not required

          6. Female aged 20-70 years old at the time of consent acquisition

          7. Baseline left ventricular ejection fraction (LVEF) measured by ECHO or MUGA of &gt;=50%

          8. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1

          9. Patients who have maintained major organ functions, meeting all of the following
             criteria on a test within 28 days before enrollment. If there are multiple test
             results during this period, that obtained immediately before enrollment should be
             adopted.

        (1) Neutrophil count: &gt;=1,500/mm3 (2) Platelet count: &gt;=100,000/mm 3 (3) Hemoglobin: &gt;=9.0
        g/dL (4) Total bilirubin: &lt;=1.5 mg/dL (5) AST (GOT), ALT (GPT): &lt;=2.5 times the ULN (&lt;=5
        times in those with liver metastasis) (6) Serum creatinine: &lt;=1.5 mg/dL 10) Patients with a
        life expectancy of at least 6 months 11) Patient who submits written consent herself after
        receiving sufficient explanation about this study 12) Patients who can undergo QOL
        investigation

        Exclusion Criteria:

          1. Patients planning to undergo radical surgery if they respond to a treatment

          2. Patients who have non-hematological adverse events assessed as Grade &gt;=3 in the Common
             Terminology Criteria for Adverse Events ver. 4.0 in the Japanese JCOG version (CTCAE
             v4.0-JCOG) at the time of enrollment

          3. Patients who have symptomatic metastases to the central nervous system or whose
             symptoms are hard to control

          4. Patients who have active double cancer

          5. Patients who have poorly controlled hypertension, or unstable angina

          6. Patients who have a past history of congestive heart failure assessed as Class ll or
             higher in the New York Heart Association (NYHA) classification, or clinically
             significant arrhythmia requiring treatment

          7. Patients with a past history of myocardial infarction within 6 months before
             enrollment

          8. Patients who are expected to undergo major surgical treatment or who had severe injury
             within 28 days before enrollment, or who require major surgical treatment during the
             study treatment period

          9. Patients with interstitial pneumonia which is symptomatic or requires treatment

         10. Pregnant women, those with a positive pregnancy test, and lactating women

         11. Patients with active systemic infection (including HCV and HBV), or who are found to
             be HIV-positive

         12. Patients with hypersensitivity against pertuzumab and trastuzumab

         13. Patients whom the investigator consider unable or unwilling to follow the protocol
             requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshinari Tamashita, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kanagawa Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norikazu Masuda, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHO Osaka National Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigehira Saji, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fukushima Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toshinari Tamashita, MD, PhD</last_name>
    <phone>+81-45-520-2222</phone>
    <email>tyamashita@kcch.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toshinari Yamashita, MD,PhD</last_name>
      <phone>+81-45-520-2222</phone>
      <email>tyamashita@kcch.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital</name>
      <address>
        <city>Ōsaka</city>
        <state>Osaka</state>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norikazu Masuda, MD,PhD</last_name>
      <phone>+81-6-6942-1331</phone>
      <email>nmasuda@alpha.ocn.ne.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.</citation>
    <PMID>22149875</PMID>
  </results_reference>
  <results_reference>
    <citation>Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2.</citation>
    <PMID>21376385</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892. Epub 2015 Jan 20.</citation>
    <PMID>25605862</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilks S, Puhalla S, O'Shaughnessy J, Schwartzberg L, Berrak E, Song J, Cox D, Vahdat L. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer. 2014 Dec;14(6):405-12. doi: 10.1016/j.clbc.2014.04.004. Epub 2014 Jun 2.</citation>
    <PMID>25024001</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

